BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 22522457)

  • 1. Inhibition of Eg5 acts synergistically with checkpoint abrogation in promoting mitotic catastrophe.
    Chen Y; Chow JP; Poon RY
    Mol Cancer Res; 2012 May; 10(5):626-35. PubMed ID: 22522457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of mitotic catastrophe on abrogation of the G2 DNA damage checkpoint by UCN-01.
    On KF; Chen Y; Ma HT; Chow JP; Poon RY
    Mol Cancer Ther; 2011 May; 10(5):784-94. PubMed ID: 21430130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint.
    Chin GM; Herbst R
    Mol Cancer Ther; 2006 Oct; 5(10):2580-91. PubMed ID: 17041103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.
    Tse AN; Schwartz GK
    Cancer Res; 2004 Sep; 64(18):6635-44. PubMed ID: 15374978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation.
    Vogel C; Hager C; Bastians H
    Cancer Res; 2007 Jan; 67(1):339-45. PubMed ID: 17210716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.
    Xiao Z; Xue J; Sowin TJ; Rosenberg SH; Zhang H
    Oncogene; 2005 Feb; 24(8):1403-11. PubMed ID: 15608676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy.
    Xiao Z; Xue J; Sowin TJ; Zhang H
    Mol Cancer Ther; 2006 Aug; 5(8):1935-43. PubMed ID: 16928813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics.
    Xiao Z; Xue J; Semizarov D; Sowin TJ; Rosenberg SH; Zhang H
    Int J Cancer; 2005 Jul; 115(4):528-38. PubMed ID: 15688426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5.
    Kapoor TM; Mayer TU; Coughlin ML; Mitchison TJ
    J Cell Biol; 2000 Sep; 150(5):975-88. PubMed ID: 10973989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1.
    Yu Q; La Rose J; Zhang H; Takemura H; Kohn KW; Pommier Y
    Cancer Res; 2002 Oct; 62(20):5743-8. PubMed ID: 12384533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. M2, a novel anthracenedione, elicits a potent DNA damage response that can be subverted through checkpoint kinase inhibition to generate mitotic catastrophe.
    Evison BJ; Pastuovic M; Bilardi RA; Forrest RA; Pumuye PP; Sleebs BE; Watson KG; Phillips DR; Cutts SM
    Biochem Pharmacol; 2011 Dec; 82(11):1604-18. PubMed ID: 21889927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 6,7-Dimethoxy-3-(3-methoxyphenyl)isoquinolin-1-amine induces mitotic arrest and apoptotic cell death through the activation of spindle assembly checkpoint in human cervical cancer cells.
    Chung KS; Choi HE; Shin JS; Cho YW; Choi JH; Cho WJ; Lee KT
    Carcinogenesis; 2013 Aug; 34(8):1852-60. PubMed ID: 23615402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitotic slippage and expression of survivin are linked to differential sensitivity of human cancer cell-lines to the Kinesin-5 inhibitor monastrol.
    Asraf H; Avunie-Masala R; Hershfinkel M; Gheber L
    PLoS One; 2015; 10(6):e0129255. PubMed ID: 26035434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells.
    Hirose Y; Berger MS; Pieper RO
    Cancer Res; 2001 Aug; 61(15):5843-9. PubMed ID: 11479224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A role for Chk2 in DNA damage induced mitotic delays in human colorectal cancer cells.
    Varmark H; Kwak S; Theurkauf WE
    Cell Cycle; 2010 Jan; 9(2):312-20. PubMed ID: 20023427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drosophila FMRP participates in the DNA damage response by regulating G2/M cell cycle checkpoint and apoptosis.
    Liu W; Jiang F; Bi X; Zhang YQ
    Hum Mol Genet; 2012 Nov; 21(21):4655-68. PubMed ID: 22843500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900.
    Blackwood E; Epler J; Yen I; Flagella M; O'Brien T; Evangelista M; Schmidt S; Xiao Y; Choi J; Kowanetz K; Ramiscal J; Wong K; Jakubiak D; Yee S; Cain G; Gazzard L; Williams K; Halladay J; Jackson PK; Malek S
    Mol Cancer Ther; 2013 Oct; 12(10):1968-80. PubMed ID: 23873850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sterigmatocystin-induced checkpoint adaptation depends on Chk1 in immortalized human gastric epithelial cells in vitro.
    Jiang X; Wang J; Xing L; Shen H; Lian W; Yi L; Zhang D; Yang H; Liu J; Zhang X
    Arch Toxicol; 2017 Jan; 91(1):259-270. PubMed ID: 26914363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of the mitotic inhibitor monastrol with human kinesin Eg5.
    DeBonis S; Simorre JP; Crevel I; Lebeau L; Skoufias DA; Blangy A; Ebel C; Gans P; Cross R; Hackney DD; Wade RH; Kozielski F
    Biochemistry; 2003 Jan; 42(2):338-49. PubMed ID: 12525161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe.
    Castedo M; Perfettini JL; Roumier T; Yakushijin K; Horne D; Medema R; Kroemer G
    Oncogene; 2004 May; 23(25):4353-61. PubMed ID: 15048074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.